Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 2/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31659110 | 0.89 | DRD2 (0.45) | DRD2KDM1AMAOBCTSKBTK | |
| SCHEMBL12995641 | 0.85 | EPHX1 (0.56) | CA1CA2KMT2AL3MBTL1EPHX1 | |
| SCHEMBL13809020 | 0.81 | ALDH1A1 (0.34) | DRD2GAAKMT2AEPHX1 | |
| SCHEMBL12811829 | 0.81 | EPHX1 (0.42) | KMT2AEPHX1 | |
| SCHEMBL8275250 | 0.81 | BTK (0.41) | DRD2KDM1AMAOBCTSKBTK | |
| SCHEMBL3702152 | 0.80 | BTK (0.61) | DRD2KDM1AMAOBCTSKBTK | |
| SCHEMBL3702157 | 0.80 | BTK (0.61) | DRD2KDM1AMAOBCTSKBTK | |
| SCHEMBL1406894 | 0.80 | BTK (0.61) | DRD2KDM1AMAOBCTSKBTK | |
| SCHEMBL10343938 | 0.80 | BTK (0.61) | DRD2KDM1AMAOBCTSKBTK | |
| SCHEMBL12995650 | 0.80 | HSD11B1 (0.51) | CTSKCA1CA2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100305315-A1 | Process for the preparation of 2-(primary/secondary amino)hydrocarbyl)-carbamoyl-7-oxo-2,6-diaza-bicyclo [3.2.0.]heptane-6-sulfonic acid derivatives | BASILEA PHARMACEUTICA AG | 2010-12-02 | — | — | US | disclosed |
| US-20100305315-A1 | Process for the preparation of 2-(primary/secondary amino)hydrocarbyl)-carbamoyl-7-oxo-2,6-diaza-bicyclo [3.2.0.]heptane-6-sulfonic acid derivatives | BASILEA PHARMACEUTICA AG | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305315-A1 | Process for the preparation of 2-(primary/secondary amino)hydrocarbyl)-carbamoyl-7-oxo-2,6-diaza-bicyclo [3.2.0.]heptane-6-sulfonic acid derivatives | C9, THOC2, ODC1 | DRD2 4482/4885KDM1A 927/4885MAOB 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.